|
|
|
| Sequential Treatment of Adult APL Patients with All Trans Retinoic Acid Combined with Arsenic |
| SHI Rui, WEN Jing, WU Wen, et al |
| Xi'an Central Hospital and Xi'an Institute of Hematology,Xi'an Shaanxi 710004 |
|
|
|
|
Abstract 【Objective】To investigate the efficacy of all trans retinoic acid (ATRA) combined with arsenic in sequential treatment of acute promyelocytic leukemia (APL). 【Methods】 The clinical data of 94 APL patients admitted to our hospital were retrospectively analyzed. They were divided into observation group and control group according to different treatment methods, with 47 cases in each group. The control group was treated with ATRA, and the observation group was treated with arsenic based sequential therapy on the basis of the control group. Complete remission (CR) rate and 1-year cumulative survival rate were compared between the two groups. Time for CR patients to reach CR, PML-RARα. The negative conversion rate, recurrence rate, promyelocyte ratio, total leukocyte count and adverse reactions were compared. 【Results】The number of CR cases obtained and the number of CR cases not obtained in the observation group were 41 (87.23%) and 6 (12.77%) respectively, while the number of CR cases obtained and the number of CR cases not obtained in the control group were 40 (85.11%) and 7 (14.89%) respectively, and there was no significant difference between the two groups (P>0.05). The time for patients in the observation group to reach CR was significantly shorter than that in the control group.PML-RARα in the observation group. The negative conversion rate was higher than that of the control group, and the recurrence rate was significantly lower than that of the control group, and the difference was statistically significant (P<0.05). There was no significant difference in the percentage of promyelocytes and total leukocytes between the two groups before treatment (P>0.05); After treatment, the percentage of promyelocytes and total leukocytes in the two groups were significantly lower than those before treatment (P<0.05), and the percentage of promyelocytes and total leukocytes in the observation group were significantly lower than those in the control group (P<0.05). There was no significant difference in the 1-year cumulative survival rate between the two groups of CR patients (P>0.05), and there was no significant difference in the total adverse reaction rate between the two groups of CR patients (P>0.05). 【Conclusion】 The sequential treatment of APL patients with ATRA combined with arsenic is satisfactory. PML-RARα. The negative conversion rate is high, the recurrence rate is low, the long-term survival rate is high, and the drug safety of the two treatment methods is high.
|
|
Received: 23 March 2022
|
|
|
|
|
|
[1] JIMENEZ J J,CHALE R S,ABAD A C,et al.Acute promyelocytic leukemia (APL):a review of the literature[J].Oncotarget,2020,11(11):992-1003.
[2] 于丽,吴静,王迪,等.急性早幼粒细胞白血病细胞分化的调控机制新进展[J].中国免疫学杂志,2019,35(8):1003-1006.
[3] NI X,HU G,CAI X.The success and the challenge of all-trans retinoic acid in the treatment of cancer[J].Crit Rev Food Sci Nutr,2019,59(1):71-80.
[4] ABAZA Y,KANTARJIAN H,GARCIA-MANERO G,et al.Long-term outcome of acute promyelocytic leukemia treated with all-trans-retinoic acid,arsenic trioxide,and gemtuzumab[J].Blood,2017,129(10):1275-1283.
[5] 中华医学会血液学分会,中国医师协会血液科医师分会.中国急性早幼粒细胞白血病诊疗指南(2018年版)[J].中华血液学杂志,2018,39(3):179-183.
[6] STAHL M,TALLMAN M S.Differentiation syndrome in acute promyelocytic leukaemia[J].Br J Haematol,2019,187(2):157-162.
[7] LIANG C,PENG C J,WANG L N,et al.Arsenic trioxide and all-trans retinoic acid suppress the expression of FLT3-ITD[J].Leuk Lymphoma,2020,61(11):2692-2699.
[8] 万鼎铭,柳飞,姜中兴,等.急性早幼粒细胞白血病长期无病生存的临床分析[J].中国实用医刊,2016,43(8):88-90.
[9] 曾昭宇,周箭,陈果.AS2O3+ATRA联合VAD方案治疗首诊急性早幼粒细胞白血病的疗效分析[J].癌症进展,2018,16(7):854-857.
[10] 卫琴.全反式维甲酸与三氧化二砷联合对急性早幼粒细胞白血病的有效性评价[J].临床和实验医学杂志,2017,16(1):65-68.
[11] 李国辉,范玉贞,陈任安,等.三氧化二砷治疗急性早幼粒细胞白血病患者的疗效及预后分析[J].国际输血及血液学杂志,2019,42(4):296-304.
[12] 张倩,隋美娟,周晋.亚砷酸治疗急性早幼粒细胞白血病的长期疗效及毒副作用[J].中国新药杂志,2016,25(8):888-892. |
|
|
|
2022, Vol. 39 
